(188) The Female Genitopelvic Pain Subcommittee of the International Consultation of Sexual Medicine: Update on a systematic review of the efficacy and safety of pharmacological, surgical, psychological, and physical therapy treatments for vulvodynia
Authors: Pukall C , Bergeron S , Krapf J , Hartmann D , Carvalho J , Garrity C , Villanueva G , Matsoukas D , Dewitte M , Kellogg-Spadt S , Goldstein A , Murina F , Giraldi A 
Published: May 2023

Introduction

Literature on vulvodynia treatment is heterogeneous in terms of intervention type and study quality. A recently published systematic review (SR) of treatments focusing on randomized controlled trials (RCTs) and non-RCTs for provoked vestibulodynia (a vulvodynia subtype) concluded that most studies had very low certainty of evidence, which limited the ability to draw conclusions. The authors noted that their strict eligibility criteria resulted in a restricted number of included studies. It suggests a need for broader, more inclusive SRs to be conducted, the results of which could inform much needed intervention recommendations for vulvodynia.

Objective

The Female Genitopelvic Pain Subcommittee is conducting a SR of treatments for vulvodynia to assess their effectiveness, safety, and acceptability. The results will provide stakeholders with empirically based treatment recommendations for patients with vulvodynia.

Methods

Selection criteria: Interventions of interest include pharmacological, surgical, psychological, and physical therapy treatments of premenopausal women with clinician-diagnosed vulvodynia (primary, secondary), defined as idiopathic, chronic (≥3 months) vulvar pain. Included studies are RCTs, SRs, and comparative observational studies. The primary outcomes are pain and sexual outcomes, and safety and adverse events, with additional outcomes focusing on mood and quality of life. Selection of studies was done in DistillerSR by two independent reviewers. Conflicts were resolved by discussion or by involving a third reviewer with excluded studies documented. Full-text screening is adhering to this same process. Search methods: A comprehensive search strategy was developed by an information specialist and was peer reviewed. Numerous electronic databases were searched. No language limit was used, and a date limit was set (1997 or later). Published filters for controlled trials and other study designs were applied. PubMed/MEDLINE was used to develop the search strategy, which was then translated into other databases. A limited grey literature search was also conducted. Data collection and analysis: Data extraction and risk of bias assessment (ROB) will be done in DistillerSR using pre-piloted data extraction forms. Studies will be extracted by one reviewer and independently checked by a second reviewer. Disagreements will be resolved by discussion or by involving a third reviewer. We will extract study characteristics and outcome data. For ROB, we will use the Cochrane Risk of Bias tool and the ROBINS-I tool. We will narratively synthesize the results by comparisons and outcomes. If appropriate, we will conduct a meta-analysis for studies regarded as suitably homogeneous. Last, the certainty of the body of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.

Results

After duplicates were removed, the search yielded 10,171 references for title and abstract screening. Of these, 599 full-text articles were assessed for inclusion. All screening and preliminary data extraction will be completed by October 2022. General characteristics of the included studies including interventions identified will be presented.

Conclusions

We will report on interim progress of the SR. It will be an opportunity to gather initial input from stakeholders on this evidence-based approach. Discussion of possible multi-organization involvement will also help unify intervention recommendations for those with vulvodynia.

Disclosure

Any of the authors act as a consultant, employee or shareholder of an industry for: Andrew Goldstein – Daré Bioscience (employee), Incyte (consultant), Gynecologic Cancers Research Foundation (Board of Directors, Research Funding).